Genentech, Inc. Delays Plan on Avastin Use in Eyes According to Wall Street Journal

NEW YORK, Oct 31 (Reuters) - Biotechnology company Genentech Inc (DNA.N: Quote, Profile, Research) is delaying a plan which would make it harder for doctors to use its cancer drug Avastin as an inexpensive treatment for eye afflictions, the Wall Street Journal reported on Wednesday.

Back to news